The use of immunobiological agents for the treatment of autoimmune diseases is increasing in medical practice. Anti-TNF therapies have been increasingly used in refractory autoimmune diseases, especially rheumatoid arthritis, with promising results. However, the use of such therapies has been associated with an increased risk of developing other autoimmune diseases. In addition, the use of anti-TNF agents can cause pulmonary complications, such as reactivation of mycobacterial and fungal infections, as well as sarcoidosis and other interstitial lung diseases (ILDs). There is evidence of an association between ILD and the use of anti-TNF agents, etanercept and infliximab in particular. Adalimumab is the newest drug in this class, and some authors have suggested that its use might induce or exacerbate preexisting ILDs. In this study, we report the first case of acute ILD secondary to the use of adalimumab in Brazil, in a patient with rheumatoid arthritis and without a history of ILD.
Introduction
The use of immunobiological agents for the treatment of autoimmune diseases is increasing in medical practice. Anti-TNF therapies and therapies with B-cell-depleting agents (rituximab) have been increasingly used in refractory autoimmune diseases, especially rheumatoid arthritis (RA), systemic sclerosis, and systemic lupus erythematosus, with promising results. The TNF is an interleukin secreted by activated macrophages and T cells as a common pathway in a series of inflammatory, autoimmune, or neoplastic responses; its blockade, whether in the form of blockade of its receptors or in the form of soluble antibodies, decreases adhesion molecule expression on the endothelial surface, decreases leukocyte migration, and inhibits the production continuing her on methotrexate. A chest X-ray showed no changes suggestive of previous tuberculosis or signs of incipient ILD; and the intradermal (PPD) test for tuberculosis was negative (0 mm). One week after receiving the second dose of adalimumab (40 mg weekly), the patient started experiencing dry cough, dyspnea on moderate exertion, and daily fever (38°C). At that point, the results of chest X-ray, physical examination, and laboratory tests, including blood workup, were normal-hemoglobin, 13.1 g/dL; hematocrit, 39.2%; 8,380 leukocytes (75% neutrophils, 0.4% eosinophil, 9.8% lymphocytes); and 355,000 platelets, except for an increase in inflammatory markers (C-reactive protein, 326 mg/dL; reference value < 3 mg/dL) and in ESR (67 mm, reference value < 20.2 mm). Sputum smears for AFB and blood cultures were negative. The patient was started on empiric treatment with levofloxacin; however, she continued to have fever and dyspnea. A HRCT scan of the chest, performed two weeks after symptom onset, revealed ground-glass opacities, predominantly in the upper and middle lung fields, associated with areas of smooth interlobular septal thickening ( Figure 1 ). Therefore, a presumptive diagnosis of ILD secondary to the use of adalimumab was made. We decided to discontinue the patient from the anti-TNF agent and methotrexate and to continue her on low-dose prednisone (5 mg/ day). The patient showed progressive reduction in dyspnea, remission of fever, and normalization of inflammatory markers, without reactivation of the articular inflammatory process. Three weeks of other inflammatory cytokines. However, the use of such therapies has been associated with an increased risk of developing other autoimmune diseases, such as systemic lupus erythematosus, autoimmune hepatitis, thyroiditis, and cutaneous vasculitis. According to the literature, the use of anti-TNF agents particularly in the lung is little effective in controlling interstitial lung disease (ILD) secondary to collagenosis, and can lead to other complications, such as reactivation of mycobacterial and fungal infections, as well as sarcoidosis and other ILDs. (1) There is evidence of an association between ILD and the use of anti-TNF agents, etanercept and infliximab in particular. (2) Adalimumab is the newest drug in this class, and, because it is a humanized monoclonal antibody, it would have the potential advantage of being less immunogenic than its precursors. However, although adalimumab is infrequently used, some authors have suggested that its use might induce or exacerbate preexisting ILDs. (3) (4) (5) (6) (7) (8) (9) The objective of the present study was to report the first case of acute ILD secondary to the use of adalimumab in Brazil, in a patient with RA and without a history of ILD.
Case report
A 62-year-old female patient with a 20-year history of RA had been on methotrexate, leflunomide, and prednisone. Because the articular inflammatory process persisted, we decided to start the patient on adalimumab, patients, in the context of immunosuppression, infection should be considered as an important differential. (13) It should be borne in mind that the use of adalimumab has been associated with cases of pulmonary cryptococcosis (14) and disseminated mycobacteriosis. (15) In this clinical context, diffuse ground-glass opacities associated with intralobular septal thickening should also lead to the exclusion of other etiologies, such as viral infections or infections with Pneumocystis jiroveci, (16) alveolar hemorrhage, pulmonary congestion, and drug toxicity due to concomitant treatment with methotrexate. Bronchoscopy and bronchoalveolar lavage aid in the differential diagnosis.
In the largest sample of patients with lung injury secondary to anti-TNF therapy, 122 cases were reported (3 of which were secondary to adalimumab). The mean time to symptom onset was 26 weeks. The most common histological patterns were usual interstitial pneumonia, organizing pneumonia, diffuse alveolar damage, and even lymphocytic interstitial pneumonia. Of the cases that were followed up until the outcome was known, 40% experienced improvement in ILD, 25% had partial resolution of ILD, and 35% had no resolution of ILD, with death occurring in 29% of the patients. Predictors of poor prognosis were age > 65 years, late onset of symptoms, frequent use of other immunosuppressants (especially methotrexate), and a previous diagnosis of ILD. (2) Despite an isolated report of improvement in ILD with the use of this medication for RA, (9) it is currently recommended that adalimumab and after the onset of the condition, the results of physical examination and spirometry were normal, with an SpO 2 of 98% on room air. A second HRCT, performed three weeks after symptom onset, showed near-complete resolution of the ground-glass areas (Figure 2 ).
Discussion
The pathogenesis of anti-TNF-agent-induced lung injury remains unknown; TNF is believed to exert a pro-fibrotic action by stimulating collagen synthesis by fibroblasts and myofibroblasts. (10) In addition, an increased Th2-type lymphocyte response, (7) the action of IFN-γ unopposed by TNF, (7) and the synergistic action of methotrexate are speculated to play a role in the development of lung injury. (8, 9, 11, 12) Clinical findings are nonspecific, and include dry cough, fever, and dyspnea, (2) which can be progressive or more intense after each administration of the medication. (6) Symptoms can appear from one month (9) to three and a half years after treatment initiation.
(7) Findings on HRCT can include ground-glass opacities, foci of consolidation, reticulated patterns, and traction bronchiectasis. (6, 8) Attributing lung injury to drugs and, in the present case, to anti-TNF agents is a challenge. The diagnosis is usually presumptive, and the causal connection is determined by temporal association between drug initiation and symptom onset and by improvement after drug discontinuation, always after excluding other etiologies. In such A B Figure 2 -HRCT scan of the chest performed three weeks after the onset of the condition. A comparative analysis of the slices shows significant spontaneous improvement in the ground-glass opacities, in relation to the first scan, in the upper lung fields, in A, and at the level of the main carina, in B. There remain faint ground-glass opacities together with slight reticular infiltrates in the subpleural regions, predominantly in the right hemithorax, especially in the middle lobe.
other anti-TNF drugs should not be contraindicated in patients with preexisting ILD or other lung diseases but that caution should be exerted.
(1-3,10)
The course of cases of adalimumabinduced ILD can vary from complete remission after drug discontinuation alone to treatment refractoriness, (2, 6) with rapid progression to death. ( 3) The use of corticosteroids or intravenous immunoglobulin, or both, should be considered in selected cases. Because of the potential severity of the patient's condition, we decided in favor of CT follow-up, with scans being performed within a short interval of each other despite the resulting radiation load.
Once it is confirmed that drug reaction has occurred, it is not recommended that the drug be reintroduced or even replaced with another drug belonging to the same class of anti-TNF agents. (2, 10) Therefore, adalimumab, like other anti-TNF drugs, should always be considered in the list of drugs potentially causing lung injury.
